Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 81 to 90 of 365 total matches.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
® Vol. 65 (1678) June 12, 2023
90
Patients of stroke, transient ischemic attack, or hemiplegic ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
Respir Med 2022;
10:1137.
The Medical Letter ® Vol. 65 (1677) May 29, 2023 tocilizumab Actemra ...
The investigational anti-complement component 5a
(C5a) antibody vilobelimab (Gohibic – InflaRx) has
been granted an FDA Emergency Use Authorization
(EUA) for IV treatment of hospitalized adults
with COVID-19 beginning within 48 hours after
invasive mechanical ventilation (IMV) or extracorporeal
membrane oxygenation (ECMO) is started.
Vilobelimab is the first anti-C5a antibody to become
available in the US.
Med Lett Drugs Ther. 2023 May 29;65(1677):86-7 doi:10.58347/tml.2023.1677d | Show Introduction Hide Introduction
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
® Vol. 65 (1677) May 29, 2023
82
1. Live fecal microbiota (Rebyota) for prevention of CDI
recurrence ...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 doi:10.58347/tml.2023.1677a | Show Introduction Hide Introduction
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
et al. Cancer Med 2020; 9:6234.
The Medical Letter ® Vol. 65 (1677) May 29, 2023
The incidence ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously
called Rolontis), a granulocyte colony-stimulating
factor (G-CSF) conjugated to an Fc fragment of human
IgG4, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4 doi:10.58347/tml.2023.1677b | Show Introduction Hide Introduction
Cariprazine (Vraylar) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
be considered first.
The Medical Letter ® Vol. 65 (1677) May 29, 2023
85
ADVERSE EFFECTS — In clinical trials ...
The FDA has approved the second-generation
antipsychotic drug cariprazine (Vraylar — Abbvie) for
adjunctive treatment of major depressive disorder
(MDD) in adults. Cariprazine was previously approved
for treatment of schizophrenia and bipolar depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6 doi:10.58347/tml.2023.1677c | Show Introduction Hide Introduction
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
.
The Medical Letter ® Vol. 65 (1677) May 29, 2023The
Medical
Letter
2. DE Gordon et al. A SARS-CoV-2 protein ...
Results from a double-blind trial suggest that off-label
use of the oral antihyperglycemic drug metformin
in patients with COVID-19 may decrease the risk
of post-acute sequelae of SARS-CoV-2 infection
("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8 doi:10.58347/tml.2023.1677e | Show Introduction Hide Introduction
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
Letter ® Vol. 65 (1676) May 15, 2023
74
Table 1. Efficacy of Contraceptives for Pregnancy Prevention ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
straining, stool consistency, and quality of life,
compared to placebo.7
The Medical Letter ® Vol. 65 ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
/drug-pricing-policy.
The Medical Letter ® Vol. 65 (1675) May 1, 2023
68
In XTEND-1, patients ≥12 ...
The FDA has approved Altuviiio (Sanofi), a von
Willebrand Factor (VWF)-independent, recombinant
factor VIII concentrate, for routine prophylaxis, on-demand
treatment to control bleeding episodes, and
perioperative management of bleeding in children and
adults with hemophilia A. The manufacturer claims that
Altuviiio, which was previously called efanesoctocog
alfa, delivers normal to near-normal factor VIII levels for
most of the week with once-weekly intravenous dosing.
Med Lett Drugs Ther. 2023 May 1;65(1675):67-8 doi:10.58347/tml.2023.1675b | Show Introduction Hide Introduction
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
/drugpricing-
policy.
The Medical Letter ® Vol. 65 (1675) May 1, 2023
69
ADVERSE EFFECTS – Injection-site ...
The FDA has approved oral and injectable
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults
whose current regimen is failing. Lenacapavir is the
third drug to be approved exclusively for treatment
of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the
orally administered HIV-1 gp120-directed attachment
inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70 doi:10.58347/tml.2023.1675c | Show Introduction Hide Introduction